Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
08/2003
08/05/2003US6602912 Preferably administered along with a basic permeation enhancer and a hydroxide-releasing agent such as sodium hydroxide.
08/05/2003US6602910 Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine
08/05/2003US6602887 Chronic, bolus administration of D-threo methylphenidate
08/05/2003US6602854 Branched multimeric Apo A-I agonist compounds
08/05/2003US6602595 Ink comprising: a non-stoichiometric non-equilibrium nanostructured material; device such as electronics using such a material
08/05/2003US6602580 Material having a substance protected by deformable standoffs and method of making
08/05/2003US6602543 Nanotechnology for magnetic components
08/05/2003US6602524 Microspheres for use in the treatment of cancer
08/05/2003US6602523 Adsorbed on surface of inorganic core selected from noble metals, metal oxides, metal nitrides, metal carbides, metal phosphates, metal carbonates, metal sulfates, metal halides, carbonaceous materials, ceramics, zeolites, SiO2; high surface
08/05/2003US6602522 Omeprazole for oral administration; avoids need to use a separate or dual coating layer to physically isolate the drug and controls bioavailability by providing cohesiveness of powder upon disintegration
08/05/2003US6602521 Multiplex drug delivery system suitable for oral administration
08/05/2003US6602520 Rapidly disintegrating; tabletting medicine and excipient in presence of of water, ethanol, or isopropanol by compaction, drying the porous non-effervescent tablet
08/05/2003US6602518 Chewable product including active ingredient
08/05/2003US6602511 Lecithin, sphingolipid or galacto lipid hydrophobic surfactant and hydrophilic surfactant; oil in water emulsion; administering low water soluble drugs
08/05/2003US6602510 Eight isolated epitopes YLSGANLNV (SEQ ID NO:1), IMIGVLVGV (SEQ ID NO:2), KLBPVQLWV (SEQ ID NO:3), SMPPPGTRV (SEQ ID NO:4), KVAELVHFL (SEQ ID NO:5), YLQLVFGIEV (SEQ ID NO:6), RLLQETELV (SEQ ID NO:7), and, VVLGVVFGI (SEQ ID NO:8).
08/05/2003US6602398 Transporting cation through channel in assay using membrane comprising phospholipid bilayer or multilayer which separates two aqueous regions, and one or more channels produced from pure mixture of polyhydroxybutyrate and polyphosphate
08/05/2003US6602269 Embolic devices capable of in-situ reinforcement
08/05/2003CA2278632C Sugar-free dragee chewing sweets
08/05/2003CA2115943C Novel process for the preparation of cetrorelix lyophilisate
08/05/2003CA2101183C Microparticle preparation and production thereof
07/2003
07/31/2003WO2003062648A2 Improved determination of gas solubility, entrained gas content, and true liquid density in manufacturing processes
07/31/2003WO2003062413A1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
07/31/2003WO2003062368A1 Method for producing a water-alcohol solution and products based thereon
07/31/2003WO2003062342A1 Pressure-sensitive adhesive and patch employing the same
07/31/2003WO2003062199A2 Pace-a microspheres for delivery of antigens
07/31/2003WO2003061841A1 Electrostatic application of powder material to solid dosage forms
07/31/2003WO2003061816A1 Apparatus and process for preparing crystalline particles
07/31/2003WO2003061766A1 Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
07/31/2003WO2003061757A1 Transdermal/transmucosal preparations for electroporation
07/31/2003WO2003061742A2 Humidity-tight cartridge for a powder inhaler
07/31/2003WO2003061728A2 Oral administration of interferon-tau
07/31/2003WO2003061721A1 Film-forming compositions and methods
07/31/2003WO2003061719A1 Process for production of pressure-sensitive adhesive moldings comprising crosslinked polymers as the main component
07/31/2003WO2003061713A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity
07/31/2003WO2003061709A1 A method for preparing resinates
07/31/2003WO2003061708A1 Stabilized formulations of adenovirus
07/31/2003WO2003061707A1 Dermatological water-resistant compositions with sun screens and method for production and use of such compositions
07/31/2003WO2003061706A1 A weight management system for obese animals
07/31/2003WO2003061705A1 Weight management system for obese animals
07/31/2003WO2003061691A1 Orodispersible pharmaceutical composition comprising perindopril
07/31/2003WO2003061690A1 Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
07/31/2003WO2003061689A1 Thrombin derived peptides for promoting cardiac tissue repair
07/31/2003WO2003061688A1 Novel analgesics
07/31/2003WO2003061687A1 High-concentration preparation of soluble thrombomodulin
07/31/2003WO2003061677A1 The healthy patch with the functions of accelerating blood circulation and expelling toxin
07/31/2003WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies
07/31/2003WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases
07/31/2003WO2003061664A1 Orodispersible pharmaceutical composition comprising testosterone
07/31/2003WO2003061662A1 Orodispersible pharmaceutical composition comprising ivabradine
07/31/2003WO2003061661A1 Orally dispersible pharmaceutical piribedil composition
07/31/2003WO2003061650A1 Orodispersible pharmaceutical composition comprising mitiglinide
07/31/2003WO2003061647A1 Orodispersible pharmaceutical composition comprising 2-({2-methoxy-2- [3-(trifluoromethyl) phenyl]ethyl}amino) ethyl-4-(2-{ [2-(9h- fluoren-9-yl) acetyl]amino} ethyl)benzoate
07/31/2003WO2003061646A1 Process for producing granules containing branched amino acids
07/31/2003WO2003061644A1 Orodispersible pharmaceutical composition comprising agomelatine
07/31/2003WO2003061642A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
07/31/2003WO2003061637A1 Compositions for pulmonary administration
07/31/2003WO2003061636A2 Dna dosage forms
07/31/2003WO2003061635A2 Method and device for producing products in web form
07/31/2003WO2003061634A1 Sustained release pharmaceutical composition
07/31/2003WO2003061633A1 Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan
07/31/2003WO2003061632A1 Method of treatment of a patient requiring analgesia
07/31/2003WO2003061631A1 Highly lubricious hydrophilic coating utilizing dendrimers
07/31/2003WO2003061630A1 Tabletting process
07/31/2003WO2003061629A2 Dna dosage forms
07/31/2003WO2003061628A1 Liposome-encapsulated opioid analgesics
07/31/2003WO2003061627A1 New process 1
07/31/2003WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs
07/31/2003WO2003061624A1 Formulation for the administration of medicinal substances
07/31/2003WO2003061623A1 Solid orally-dispersible pharmaceutical formulation
07/31/2003WO2003061621A2 Dermal application system for aminolevulinic acid-derivatives
07/31/2003WO2003061620A2 Peptide-carrying bodies for immune response
07/31/2003WO2003061617A2 Method for treatment of a region of the skin of a human subject, in particular cosmetic treatment by the trans-epidermal route using projection of a liquid under pressure
07/31/2003WO2003061608A1 Water-in-oil emulsion composition and emulsion cosmetic comprising the same
07/31/2003WO2003061600A2 Device for transcutaneous drug delivery and uses therefor
07/31/2003WO2003061593A2 Novel targeted compositions for diagnostic and therapeutic use
07/31/2003WO2003061584A2 Novel substituted benzimidazole dosage forms and method of using same
07/31/2003WO2003061578A2 Compositions for treatment or prevention of bioterrorism
07/31/2003WO2003061571A2 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
07/31/2003WO2003061568A2 Methods and therapeutic compositions in the treatment of advanced cancer
07/31/2003WO2003061557A2 Levothyroxine pharmaceutical compositions, methods of making and methods of administration
07/31/2003WO2003061555A2 West nile vaccine
07/31/2003WO2003061554A2 Composition containing moutan root bark extract as active ingredient
07/31/2003WO2003061545A2 Therapeutic decorative object
07/31/2003WO2003061402A2 Reduction of renal damage in companion animals
07/31/2003WO2003061379A2 Methods for inactivation of pathogens in biological materials
07/31/2003WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome
07/31/2003WO2003035668A3 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
07/31/2003WO2003034988A3 Injectable compositions for the controlled delivery of pharmacologically active compound
07/31/2003WO2003030872A3 Compositions having a combination of particles for immediate release and for controlled release
07/31/2003WO2003028696A3 Compositions for delivery of drug combinations
07/31/2003WO2003026615A3 Modified release dosage forms
07/31/2003WO2003020242A9 Sustained release preparations
07/31/2003WO2003007995A3 Pharmaceutical preparations containing ion exchange resins charged with fluoroquinolone
07/31/2003WO2003007867A3 A salt/ion pair medicinal aerosol formulation
07/31/2003WO2002094174A3 Container and method for dispensing transdermal dosage forms
07/31/2003WO2002036169A3 Methods and compositions for enhanced delivery of bioactive molecules
07/31/2003WO2002007702A3 Liposomic formulation of clobetasol propionate
07/31/2003WO2001098348A3 Regulation of cellproliferation and differentiation using topically applied peptides
07/31/2003WO2001089679A3 Continuous production of pharmaceutical granulates
07/31/2003WO2001080902A8 A particulate complex for administering nucleic acid into a cell
1 ... 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 ... 2991